1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Virax Biolabs Signs Agreement with Europa Biosite to Commercialize Immuneselect

25 Oct 2024
Admin
News Article

Virax Biolabs Signs Agreement with Europa Biosite to Commercialize Immuneselect

Virax Biolabs enters distribution agreement with Europa Biosite to commercialize ImmuneSelect in UK & Ireland

Overview

Virax Biolabs Group Limited, an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced that it has entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the United Kingdom and Ireland through its wholly owned subsidiary Cambridge Bioscience.

Words from the CEO: Virax Biolabs

"ImmuneSelect is an important suite of profiling solutions for assessing adaptive immunity and we are pleased to partner with Europa Biosite, a leader in life science distribution across Europe," said James Foster, CEO of Virax Biolabs.
"We believe this partnership will meaningfully expand our commercial footprint in the UK and Ireland and make ImmuneSelect accessible to researchers and pharmaceutical companies as they work to better understand the role of T cell response and immune status."

Statement from Europa Biosite

"We are happy to partner with innovative companies like Virax Biolabs," commented Martijn Blommaart, director of supplier development at Europa Biosite.
"We look forward to leveraging our commercial infrastructure to quickly deliver and provide local technical support to ensure that ImmuneSelect is available in the UK & Ireland"

About ImmuneSelect

ImmuneSelect is the company's portfolio of research products dedicated to investigating adaptive immunity.
Products within the ImmuneSelect brand are for research and investigational use only and are not intended to be used as a diagnostics tool.

The European supplier: Europa Biosite

Europa Biosite is a European supplier of life science products and services, composed of six leading distribution companies: Biomol in Germany, Cambridge Bioscience in the UK and Ireland, LubioScience in Switzerland, Nordic Biosite in the Nordics and Baltics, Sanbio in Benelux and Szabo-Scandic in Austria.

About Virax Biolabs Group Limited

Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases.
Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform.